Invest in the Future of Cancer Therapy

Ymmunobio brings together leaders in immunology, oncology, cell biology, and drug development to build a differentiated pipeline of novel, first-in-class antibodies designed to address resistance to today’s treatments. With a protected IP position and strategic collaborations, we’re translating strong preclinical results into programs with clear development paths. 

If you’d like to learn more about our work, partnering opportunities, or upcoming milestones, please reach out at  info@ymmuno.bio or use the form below.